Recently, various immunotherapies directed towards different targets, especially the programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) pathway, have been revealed as favorable strategies to treat several tumor types, such as melanoma and non-small-cell lung cancer (13, 14). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.